≡

Leucine Rich Repeat Kinase 2 (LRRK2)

[Edit]

AURA17; PARK8; RIPK7; ROCO2; Dardarin ; Parkinson Disease(Autosomal Dominant)8; Leucine-rich repeat serine/threonine-protein kinase 2

Leucine Rich Repeat Kinase 2 (LRRK2)
CCC H716
HGNC 18618
MGI 1913975
PubMed 15541308
RGD 1561168
UniProt Q5S007
Wiki LRRK2
LRRK2 encodes a protein with an ankyrin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, an MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane.LRRK2 interacts with the C-terminal R2 RING finger domain of parkin, and parkin interacted with the COR domain of LRRK2. Expression of mutant LRRK2 induced apoptotic cell death in neuroblastoma cells and in mouse cortical neurons. Mutations in this gene have been associated with Parkinson's disease type 8.Four LRRK2 gene variants found are found in a third of Parkinson’s cases, but infrequent in the general population.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPH716Hu01 Recombinant Leucine Rich Repeat Kinase 2 (LRRK2) Positive Control; Immunogen; SDS-PAGE; WB.
RPH716Hu02 Recombinant Leucine Rich Repeat Kinase 2 (LRRK2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAH716Hu01 Polyclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2) WB; IHC; ICC; IP.
PAH716Hu02 Polyclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2) WB; IHC; ICC; IP.
LAH716Hu71 Biotin-Linked Polyclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2) WB; IHC; ICC.
Assay Kits SEH716Hu ELISA Kit for Leucine Rich Repeat Kinase 2 (LRRK2) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPH716Mu01 Recombinant Leucine Rich Repeat Kinase 2 (LRRK2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAH716Mu01 Polyclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Leucine Rich Repeat Kinase 2 (LRRK2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Leucine Rich Repeat Kinase 2 (LRRK2) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPH716Ra01 Recombinant Leucine Rich Repeat Kinase 2 (LRRK2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies MAH716Ra21 Monoclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2) WB; IHC; ICC; IP.
PAH716Ra01 Polyclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2) WB; IHC; ICC; IP.
Assay Kits SEH716Ra ELISA Kit for Leucine Rich Repeat Kinase 2 (LRRK2) Enzyme-linked immunosorbent assay for Antigen Detection.
  1. "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." Neuron 44:601-607(2004) [PubMed] [Europe PMC] [Abstract]
  2. "The finished DNA sequence of human chromosome 12." Nature 440:346-351(2006) [PubMed] [Europe PMC] [Abstract]
  3. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  4. "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation."Brain 128:2777-2785(2005) [PubMed] [Europe PMC] [Abstract]
  5. "The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity."Hum. Mol. Genet. 15:223-232(2006) [PubMed] [Europe PMC] [Abstract]
  6. "LRRK2 mutations are not common in Alzheimer's disease."Mech. Ageing Dev. 126:1201-1205(2005) [PubMed] [Europe PMC] [Abstract]
  7. "Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity."Proc. Natl. Acad. Sci. U.S.A. 102:16842-16847(2005) [PubMed] [Europe PMC] [Abstract]
  8. "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal degeneration."Proc. Natl. Acad. Sci. U.S.A. 102:18676-18681(2005) [PubMed] [Europe PMC] [Abstract]
  9. "LRRK2 expression linked to dopamine-innervated areas."Ann. Neurol. 59:714-719(2006) [PubMed] [Europe PMC] [Abstract]
  10. "Localization of LRRK2 to membranous and vesicular structures in mammalian brain."Ann. Neurol. 60:557-569(2006) [PubMed] [Europe PMC] [Abstract]
  11. "The familial Parkinsonism gene LRRK2 regulates neurite process morphology."Neuron 52:587-593(2006) [PubMed] [Europe PMC] [Abstract]
  12. "Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity."PLoS ONE 5:E13191-E13191(2010) [PubMed] [Europe PMC] [Abstract]
  13. "Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death."Hum. Mutat. 32:1390-1397(2011) [PubMed] [Europe PMC] [Abstract]
  14. "Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP."Hum. Mol. Genet. 21:511-525(2012) [PubMed] [Europe PMC] [Abstract]
  15. "Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers."PLoS ONE 7:E43472-E43472(2012) [PubMed] [Europe PMC] [Abstract]
  16. "RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk."Neuron 77:425-439(2013) [PubMed] [Europe PMC] [Abstract]
  17. "A method for WD40 repeat detection and secondary structure prediction."PLoS ONE 8:E65705-E65705(2013) [PubMed] [Europe PMC] [Abstract]
  18. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  19. "Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain." Mol. Cell. Biol. 34:2147-2161(2014) [PubMed] [Europe PMC] [Abstract]
  20. "Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase."Proc. Natl. Acad. Sci. U.S.A. 105:1499-1504(2008) [PubMed] [Europe PMC] [Abstract]
  21. "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease." Neuron 44:595-600(2004) [PubMed] [Europe PMC] [Abstract]
  22. "Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations."Am. J. Hum. Genet. 76:672-680(2005) [PubMed] [Europe PMC] [Abstract]
  23. "Clinical and positron emission tomography of Parkinson's disease caused by LRRK2."Ann. Neurol. 57:453-456(2005) [PubMed] [Europe PMC] [Abstract]
  24. "Clinical features of LRRK2-associated Parkinson's disease in central Norway."Ann. Neurol. 57:762-765(2005) [PubMed] [Europe PMC] [Abstract]
  25. "G2019S LRRK2 mutation in French and North African families with Parkinson's disease."Ann. Neurol. 58:784-787(2005) [PubMed] [Europe PMC] [Abstract]
  26. "An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family."Ann. Neurol. 57:918-921(2005) [PubMed] [Europe PMC] [Abstract]
  27. "Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation."Ann. Neurol. 57:933-934(2005) [PubMed] [Europe PMC] [Abstract]
  28. "Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease."Brain 128:3000-3011(2005) [PubMed] [Europe PMC] [Abstract]
  29. "Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data." Brain 128:2786-2796(2005) [PubMed] [Europe PMC] [Abstract]
  30. "Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease." Eur. J. Hum. Genet. 14:322-331(2006) [PubMed] [Europe PMC] [Abstract]
  31. "The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor." J. Med. Genet. 42:E65-E65(2005) [PubMed] [Europe PMC] [Abstract]
  32. "Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease."Lancet 365:410-412(2005) [PubMed] [Europe PMC] [Abstract]
  33. "A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease."Lancet 365:412-415(2005) [PubMed] [Europe PMC] [Abstract]
  34. "A common LRRK2 mutation in idiopathic Parkinson's disease."Lancet 365:415-416(2005) [PubMed] [Europe PMC] [Abstract]
  35. "LRRK2 mutations and Parkinsonism."Lancet 365:1229-1230(2005) [PubMed] [Europe PMC] [Abstract]
  36. "Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation."Mov. Disord. 20:1077-1078(2005) [PubMed] [Europe PMC] [Abstract]
  37. "Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics."Mov. Disord. 21:519-523(2006) [PubMed] [Europe PMC] [Abstract]
  38. "Lrrk2 pathogenic substitutions in Parkinson's disease."Neurogenetics 6:171-177(2005) [PubMed] [Europe PMC] [Abstract]
  39. "LRRK2 gene in Parkinson disease: mutation analysis and case control association study."Neurology 65:696-700(2005) [PubMed] [Europe PMC] [Abstract]
  40. "Analysis of LRRK2 functional domains in nondominant Parkinson disease."Neurology 65:1319-1321(2005) [PubMed] [Europe PMC] [Abstract]
  41. "LRRK2 mutations in Parkinson disease."Neurology 65:738-740(2005) [PubMed] [Europe PMC] [Abstract]
  42. "A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations."Neurology 65:741-744(2005) [PubMed] [Europe PMC] [Abstract]
  43. "LRRK2 R1441G in Spanish patients with Parkinson's disease."Neurosci. Lett. 382:309-311(2005) [PubMed] [Europe PMC] [Abstract]
  44. "LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease."Neurosci. Lett. 395:224-226(2006) [PubMed] [Europe PMC] [Abstract]
  45. "Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD."Parkinsonism Relat. Disord. 11:349-352(2005) [PubMed] [Europe PMC] [Abstract]
  46. "LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance."Arch. Neurol. 63:377-382(2006) [PubMed] [Europe PMC] [Abstract]
  47. "The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence."Hum. Genet. 120:857-863(2007) [PubMed] [Europe PMC] [Abstract]
  48. "Patterns of somatic mutation in human cancer genomes." Nature 446:153-158(2007) [PubMed] [Europe PMC] [Abstract]
  49. "Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls."Hum. Mutat. 29:485-490(2008) [PubMed] [Europe PMC] [Abstract]
  50. "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma." Nature 469:539-542(2011) [PubMed] [Europe PMC] [Abstract]
  51. "Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease."Parkinsonism Relat. Disord. 17:501-508(2011) [PubMed] [Europe PMC] [Abstract]
  52. "Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe."Hum. Mutat. 33:1087-1098(2012) [PubMed] [Europe PMC] [Abstract]
  53. "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease." Mov. Disord. 27:1522-1529(2012) [PubMed] [Europe PMC] [Abstract]